Fu-Jun Li

Fu-Jun Li

Auto-generated profile, based on publicly available information

Fu-Jun Li

Department of Gastroenterology, Xiangya Hospital, Central South University, Changsha, China

Research Focus & Metrics

Academic Career Length

27Years (2000-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications

15 April 2005 in Blood
Verified
Journal Article
Open access
PDF file
FLFu-Jun Li
Fu-Jun Li
NTNaohiro Tsuyama
Naohiro Tsuyama
HIHideaki Ishikawa
Hideaki Ishikawa
MOMasanori Obata
Masanori Obata
SASaeid Abroun
Saeid Abroun
MKMichio M. Kawano
Michio M. Kawano
CD45, a receptor-type tyrosine phosphatase, is required for interleukin-6 (IL-6)-induced proliferation in human myeloma cells, which express the shortest isoform, CD45RO, but not the longest isoform, CD45RA. Here, we showed that IL-6 induced the translocation of CD45 to lipid rafts in an isoform-dependent manner. In myeloma cells, CD45RO was translocated to lipid rafts more rapidly than CD45RB, but exogenously expressed CD45RA was not translocated. When an IL-6Rα-transfected B-cell line was stimulated with IL-6, CD45RA was not translocated, although CD45RB was. We further confirmed that the translocated CD45 bound to IL-6Rα, Lyn, and flotillin-2, and this was followed by the dephosphorylation of the negative regulatory Tyr507 of Lyn. CD45 also bound to phosphoprotein associated with glycosphingolipid-enriched microdomains (PAGs), which were subsequently dephosphorylated, resulting in the release of C-terminal src kinase (Csk) from lipid rafts. Therefore, these results indicate that a rapid translocation of CD45RO to lipid rafts may be responsible for IL-6-induced proliferation, and that the change from CD45RA to CD45RO confers the ability to respond to IL-6 in human myeloma cells. (Blood. 2005;105:3295-3302)

30 January 2019 in Cell Biochemistry and Function
Verified
Journal Article
Open access
PDF file
YYYanqiu You
Yanqiu You
YLYanhong Liu
Yanhong Liu
FLFujun Li
Fujun Li
FMFengyun Mu
Fengyun Mu
CZCaijun Zha
Caijun Zha
Neutrophils participate in the regulation of pathogens by phagocytosis as well as by generating neutrophil extracellular traps (NETs). Antiphospholipid antibodies, particularly those targeting beta‐2‐glycoprotein I (β2GPI), stimulate monocytes, platelets, and endothelial cells with prothrombotic participation. This study aimed to explore NET generation in response to anti‐β2GPI/β2GPI. A series of experiments involving the separation of primary human leukocytes, NETosis quantification using propidium iodide, exploration of NETosis by fluorescence microscopy, western blotting, examination of free Zn2+ using FluoZin‐3, and reactive oxygen species (ROS) examination with dihydrorhodamine 123 were performed in this study. We found that anti‐β2GPI/β2GPI triggered NETosis, resembling phorbol 12‐myristate 13‐acetate (PMA)‐induced NETosis in magnitude and morphology. The anti‐β2GPI/β2GPI complex in isolation stimulated NETs without relying on p38, protein kinase B (AKT), extracellular signal‐related kinase (ERK) 1/2, and zinc signals. NET generation was unaffected by the NADPH oxidase suppressor DP1. The anti‐β2GPI/β2GPI complex stimulated ROS generation without relying on NADPH oxidase, which may participate in NET generation triggered via the anti‐β2GPI/β2GPI complex. In summary, our results indicate that the anti‐β2GPI/β2GPI complex reinforced NET generation by relying on ROS.The significance of the paper in the context of current knowledge: Neutrophils as one of the first lines of defence and essential in the response to pathogen invasion. They eradicate bacteria via phagocytosis or by releasing antimicrobial proteins in degranulation. In this study, we explored the capability of anti‐β2GPI/β2GPI to stimulate NETosis, demonstrating that anti‐β2GPI/β2GPI is a promising method for triggering NET. Anti‐β2GPI/β2GPI induced ROS generation without relying on NADPH oxidase, which contributes to NETosis independently of ERK1/2, Zn2+, or AKT. Our results showed that anti‐β2GPI/β2GPI triggered NETosis, resembling PMA‐induced NETosis in magnitude as well as morphology. The anti‐β2GPI/β2GPI complex in isolation stimulated NETs without relying on p38, AKT, ERK1/2, or zinc signals. The anti‐β2GPI/β2GPI complex stimulated ROS generation without relying on NADPH oxidase, which may participate in NET generation triggered via the anti‐β2GPI/β2GPI complex.

1 January 2000 in Thermal Medicine(Japanese Journal of Hyperthermic Oncology)
Verified
Journal Article
Open access
PDF file
KTKiyoshi Tanabe
Kiyoshi Tanabe
HYHiroyoshi Yuki
Hiroyoshi Yuki
QZQingli Zhao
Qingli Zhao
FLFu-Jun Li
Fu-Jun Li
YAYoko Arai
Yoko Arai
TKTakashi Kondo
Takashi Kondo
Hyperthermia (HT) has been recognized as an effective and attractive tool in anticancer therapy. However, the results obtained in therapy by HT alone have been only partially satisfactory. Consequently, attention has focused on the search for substances able to sensitize tumor cells to the damage caused by HT without reducing the capacity of normal cells. It has been reported that the tumor cell death in HT is mediated by apoptosis. Activation of a preprogrammed cascade of molecular events will result in DNA degradation and nuclear fragmentation, leading to apoptosis. However, the pathways which can induce apoptosis varies in different cells. If we could discover common stimuli which could induce apoptosis in all types of cells, we would obtain a new anticancer therapy against all types of tumor cells. In this report, we overviewed both mechanisms of HT-induced apotosis, and the substances used to enhance HT-induced apoptosis. Moreover, we provide evidence for the role of intracellular Ca2+concentration in HT-induced apoptosis.

16 November 2004 in Blood
Verified
Journal Article
Open access
XZXu Zheng
Xu Zheng
HIHideaki Ishikawa
Hideaki Ishikawa
NTNaohiro Tsuyama
Naohiro Tsuyama
SASaeid Abroun
Saeid Abroun
SLShangqin Liu
Shangqin Liu
MKMichio M. Kawano
Michio M. Kawano
CD19 is a B cell-specific membrane protein belonging to immunoglobulin superfamily, and acts as a positive or negative regulator in B cell signaling. Although plasma cells still express CD19, CD19 expression is lost in malignant plasma cells with the progression of multiple myeloma (MM) including monoclonal gammopathy of undermined significance (MGUS). To understand the pathological significance of loss of CD19 in human myelomas, we examined the biological effect of CD19 expression on myeloma cells by generating CD19 transfectants of a myeloma cell line, U266. CD19 transfectants showed slower growth rate in vitro than controls, such as mock and ΔCD19 transected with a truncated form of CD19. The growth-inhibitory effect was CD19-specific and presumably due to the intracellular signaling events via CD19 because this effect was not observed in ΔCD19. Furthermore, serum withdrawal rapidly induced the apoptosis of the CD19-transfectants that was rescued by insulin-like growth factor (IGF-I) as compared with CD19− controls. These may suggest that the CD19 transfectants are likely to be dependent on the growth factors, such as IGF-I, to survive and proliferate, and thus, susceptible to the serum deprivation-induced apoptosis. IGF-I activates extracellular signal-regulated kinase (ERK) 1/2 and phosphatidylinositol-3-kinase (PI-3K) that are important for proliferation of myeloma cells. Western bolt analysis showed that IGF-1-induced activation of ERK1/2 was reduced in the CD19 transfectants, although the similar levels of IGF-I receptors were expressed in the CD19 transfectants and CD19− controls. In contract, CD19 failed to inhibit the IGF-I-mediated PI-3K/AKT activation, whereas a downstream target in the PI-3K pathway, p70S6 kinase activation was decreased in the CD19 transfectants. However, the p70S6 kinase activity could be influenced by both ERK1/2 and PI-3K pathways after IGF-1 stimulation, and the MAPK pathway seems to be a major regulator for myeloma cell growth. Our results, therefore, suggest that the recovering expression of CD19 molecules and genes in human myeloma cells may be an important consideration in therapeutic approaches in human MM.